For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
LPI (LP Information)' newest research report, the "Insulin Industry Forecast" looks at past sales and reviews total world Insulin sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin sales for 2023 through 2029. With Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin industry.
This Insight Report provides a comprehensive analysis of the global Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin.
The global Insulin market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The major players in China Insulin market include Novo Nordisk, Eli Lilly, etc. The top 2 players occupy about 60% shares of the whole market. Tianjin and Jiangsu are main markets, they occupy about 60% of the whole market. Regular Human Insulin is the main type, with a share over 60%. Long Acting and Intermediate Acting are the main applications, which holds a share about 70%.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Animal Insulin
- Regular Human Insulin
- Insulin Analogue
Segmentation by application
- Short Acting
- Intermediate Acting
- Long Acting
- Pre-Mix Insulin
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Novo Nordisk
- Eli Lilly
- Sanofi-Aventis
- Tonghua Dongbao
- Ganlee
- United Laboratory
- Jiangsu Wanbang
Key Questions Addressed in this Report
What is the 10-year outlook for the global Insulin market?
What factors are driving Insulin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin market opportunities vary by end market size?
How does Insulin break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?